GlassScriptPhysician profile
Indre M Rudaitis
NPI 1801930789
$3,088.40
in general payments reported to CMS, 2019-2025
19 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $171 · 2021: $226 · 2022: $1,247 · 2023: $530 · 2024: $367 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $1,046.82 | 2022 | |
| Sun Pharmaceutical Industries INC. | $316.41 | 2020-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $236.57 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $216.53 | 2023-2024 | Acthar |
| Oyster Point Pharma, INC. | $192.92 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $163.35 | 2023-2025 | Durysta, Xen Glaucoma Treatment System |
| Shire North American Group INC | $155.66 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $116.48 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.23 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $106.13 | 2022-2025 | Vyzulta, Miebo |
| Alcon Vision LLC | $90.69 | 2022-2025 | Rocklatan |
| Amgen INC. | $87.54 | 2025 | Tepezza |
| Thea Pharma INC. | $63.33 | 2023-2024 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $51.19 | 2019-2022 | |
| Allergan, INC. | $43.60 | 2020-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $39.70 | 2024 | Vevye |
| Akorn, INC. | $19.19 | 2020 | |
| Tearlab Corp | $18.70 | 2023 | Tearlab Osmolarity System |
| Biotissue Holdings INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indre Rudaitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.